8月19日，先健科技(01302)盘中上涨5.0%，截至13:06，报2.31元/股，成交8188.02万元。 先健科技专注于心脑血管和外周血管介入医疗器械的研发、生产及全球化发展，产品在国内市场占据领 先地位，并拓展至全球120多个国家和地区。公司已获得2,426项高质量专利，15款产品通过NMPA创新 医疗器械审查程序，持续推动技术突破与国际化发展。 8月29日，先健科技将披露2025财年中报。 本文源自：金融界 作者：行情君 截至2024年年报，先健科技营业总收入13.04亿元、净利润2.22亿元。 ...

8月6日，先健科技(01302)盘中上涨5.47%，截至09:30，报2.12元/股，成交517.86万元。 作者：行情君 截至2024年年报，先健科技营业总收入13.04亿元、净利润2.22亿元。 本文源自：金融界 先健科技专注于心脑血管和外周血管介入医疗器械的研发、生产及全球化发展，产品在国内市场占据领 先地位，并拓展至全球120多个国家和地区。公司已获得2,426项高质量专利，15款产品通过NMPA创新 医疗器械审查程序，持续推动技术突破与国际化发展。 ...

Core Viewpoint - Xianjian Technology (01302) has shown a significant increase in stock price and continues to lead in the cardiovascular and peripheral vascular interventional medical device market, with a strong focus on innovation and global expansion [1][2]. Group 1: Company Performance - As of July 30, Xianjian Technology's stock price rose by 5.42%, reaching 2.14 CNY per share, with a trading volume of 46.69 million CNY [1]. - For the fiscal year ending 2024, the company reported total revenue of 1.304 billion CNY and a net profit of 222 million CNY [2]. Group 2: Product and Market Position - The company specializes in the research, development, and production of medical devices for cardiovascular and peripheral vascular interventions, holding a leading position in the domestic market [1]. - Xianjian Technology has expanded its products to over 120 countries and regions globally, demonstrating its international growth strategy [1]. - The company has secured 2,426 high-quality patents and has 15 products that have passed the NMPA innovative medical device review process, indicating a strong commitment to technological advancement [1].